A randomized phase 3 trial comparing pemetrexed/carboplatin and docetaxel/carboplatin as first-line treatment for advanced, nonsquamous non-small cell lung cancer.
about
Network meta-analysis of erlotinib, gefitinib, afatinib and icotinib in patients with advanced non-small-cell lung cancer harboring EGFR mutationsSystemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline UpdateNCCTG N0821 (Alliance): a phase II first-line study of pemetrexed, carboplatin, and bevacizumab in elderly patients with advanced nonsquamous non-small-cell lung cancer with good performance statusPRONOUNCE: randomized, open-label, phase III study of first-line pemetrexed + carboplatin followed by maintenance pemetrexed versus paclitaxel + carboplatin + bevacizumab followed by maintenance bevacizumab in patients ith advanced nonsquamous non-sSafety profiles of non-small cell lung cancer patients treated with pemetrexed plus carboplatin: a real-world retrospective, observational, cohort study.Meta-analysis of pemetrexed plus carboplatin doublet safety profile in first-line non-squamous non-small cell lung cancer studies.Critical appraisal of pemetrexed in the treatment of NSCLC and metastatic pulmonary nodules.Sequential treatment of icotinib after first-line pemetrexed in advanced lung adenocarcinoma with unknown EGFR gene status.Pemetrexed plus platinum as the first-line treatment option for advanced non-small cell lung cancer: a meta-analysis of randomized controlled trials.Phase Ib study evaluating a self-adjuvanted mRNA cancer vaccine (RNActive®) combined with local radiation as consolidation and maintenance treatment for patients with stage IV non-small cell lung cancer.Systematic review of efficacy and safety of pemetrexed in non-small-cell-lung cancer.The challenge of using biomarkers and molecularly targeted drugs to improve cure rate in early stage non-small cell lung cancerEfficacy and safety of docetaxel for advanced non-small-cell lung cancer: a meta-analysis of Phase III randomized controlled trials.Efficacy of pemetrexed plus platinum doublet chemotherapy as first-line treatment for advanced nonsquamous non-small-cell-lung cancer: a systematic review and meta-analysis.The role of docetaxel in the treatment of non-small cell lung cancer lung cancer: an update.Elderly subset analysis of randomized phase III study comparing pemetrexed plus carboplatin with docetaxel plus carboplatin as first-line treatment for patients with locally advanced or metastatic non-small cell lung cancer.Gefitinib frequently induces liver damage in patients with lung adenocarcinoma previously treated by chemotherapyPemetrexed in maintenance treatment of advanced non-squamous non-small-cell lung cancer.Pemetrexed for the treatment of non-small cell lung cancer.The continuing role of chemotherapy for advanced non-small cell lung cancer in the targeted therapy era.Thyroid transcription factor 1 expression is associated with outcome of patients with non-squamous non-small cell lung cancer treated with pemetrexed-based chemotherapy.Relationship between efficacy outcomes and weight gain during treatment of advanced, non-squamous, non-small-cell lung cancer patients.Circulating Cell-Free DNA and Circulating Tumor Cells as Prognostic and Predictive Biomarkers in Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Chemotherapy.Serum proteomic test in advanced non-squamous non-small cell lung cancer treated in first line with standard chemotherapy.Weight gain as a surrogate marker of longer survival in advanced non-small cell lung cancer patients.Maintenance therapy with pemetrexed versus docetaxel after induction therapy with carboplatin and pemetrexed in chemotherapy-naïve patients with advanced non-squamous non-small-cell lung cancer: a randomized, phase II study.Bevacizumab in combination with different platinum-based doublets in the first-line treatment for advanced nonsquamous non-small-cell lung cancer: A network meta-analysis.Evaluation of calculating carboplatin dosage in carboplatin-pemetrexed therapy as the first-line therapy for Chinese patients with advanced lung adenocarcinoma.Docetaxel increases the risk of severe infections in the treatment of non-small cell lung cancer: a meta-analysis
P2860
Q21132357-C9B70492-202D-4AD7-9ABF-85741AEFCED5Q30356434-B0D11E2F-E7A1-468B-A316-05FF71A4A172Q33417324-FA42EABF-EC8D-4C6F-9A53-F114533E0503Q33418542-C87C5BA5-0215-410E-A44D-BC368BD9E2C8Q33439970-F67BD0C4-E75C-414A-AE95-D40158E50C05Q33439985-E7B6FC74-19D6-4712-8687-9B9E93A91B55Q33754141-948E8718-A47A-489B-87C5-2199F69DE304Q33995172-701248F8-05E4-4477-BA1C-27529AA2B28AQ34277874-69643B3D-8A95-4E7A-AFC0-0E209C18FFFDQ34333155-1BB7E84F-03C5-4F6F-B867-D6D95AE0F453Q35109837-C862E4F7-2D5D-464A-9AC3-593EF8DB9AC1Q35290441-7E6A6720-7218-443B-AC96-B4B942C01709Q35766183-AC44525E-6B1D-4171-AF95-9AF35D5D3A30Q35978881-5F7A9C0C-EE20-4C4E-8866-C088891E0044Q36142491-2438EB95-6E46-48F1-98A6-4B3FC610BF25Q37365319-A6A0AD33-F1F4-4E0B-A57C-DC80CD32E6E9Q37566619-88E2A6CE-5EDE-43A5-93E5-842575C64870Q37566838-E80FF57E-51D5-44E3-9F99-09C9376326F7Q38107552-69F67C1F-F5D4-4195-9EB0-D65124665F00Q38155855-4E4EFC12-F44A-4361-928F-55B53F606409Q38952088-C2E3B055-E82D-4CC7-BCD3-1CEDCC54BBF0Q39741230-29988119-8A0A-45A6-8792-32C568F572D5Q40206402-E8CE3828-116A-4840-99F1-747311A80B54Q40451221-2118874A-B761-4440-95D7-4809C02B9B0BQ41544840-AD0DF00B-0391-4364-9371-F9C49158F045Q43654035-2CD4AA83-8710-442C-9519-DAE37F142556Q47420701-B6F217D3-244D-4044-AD20-E61CF2111B64Q48150694-59F55F61-65CA-4666-A83E-3757626108C8Q58718145-E09B28E5-1EEB-4655-B07C-C40FFC2B3B31
P2860
A randomized phase 3 trial comparing pemetrexed/carboplatin and docetaxel/carboplatin as first-line treatment for advanced, nonsquamous non-small cell lung cancer.
description
2011 nî lūn-bûn
@nan
2011 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
A randomized phase 3 trial com ...... us non-small cell lung cancer.
@ast
A randomized phase 3 trial com ...... us non-small cell lung cancer.
@en
type
label
A randomized phase 3 trial com ...... us non-small cell lung cancer.
@ast
A randomized phase 3 trial com ...... us non-small cell lung cancer.
@en
prefLabel
A randomized phase 3 trial com ...... us non-small cell lung cancer.
@ast
A randomized phase 3 trial com ...... us non-small cell lung cancer.
@en
P2093
P1476
A randomized phase 3 trial com ...... us non-small cell lung cancer.
@en
P2093
Dae Ho Lee
Helen Barraclough
Joo-Hang Kim
José Rodrigues-Pereira
Luis Martínez-Barrera
Manuel Magallanes
Mauro Orlando
Maximiliano van Kooten
Vinod Ganju
P304
P356
10.1097/JTO.0B013E318226B5FA
P577
2011-11-01T00:00:00Z